We have investigated the cause of dual serological reactivity to human immunodeficiency virus (HIV) types 1 and 2, a common occurrence in West Africa. Serum specimens from 111 individuals from Côte d'Ivoire classified by commercial western blot as HIV-1 (n = 15), HIV-2 (32), and dually reactive (64) were further tested by more specific serological tests (a synthetic peptide enzyme immunoassay [Pepti-LAV 1/2] and western blots prepared from antigen in which oligomeric forms of the transmembrane protein were disrupted by trichloroacetic acid [WB-TCA]). Peripheral blood mononuclear cells were tested for HIV-1 and HIV-2 with the polymerase chain reaction (PCR) and virus culture. Of 104 samples that were concordant by both WB-TCA and Pepti-LAV, 82 (79%) were confirmed by PCR results. Virus culture was concordant with serology for specimens (35/38) in which any virus was detected. Our findings indicate that mixed HIV-1/HIV-2 infections are common in Côte d'Ivoire, and suggest that natural infection by one HIV type does not prevent heterologous infection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0140-6736(92)91406-x | DOI Listing |
Cell Mol Biol (Noisy-le-grand)
November 2024
Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso.
HIV-2 infection although less virulent compared to HIV-1 is endemic in many parts of West Africa. In Burkina Faso, few data exist on HIV-2 genotypic resistance. The objective of this study was to assess HIV-2 genotypic resistance and viral load in adult patients infected with HIV-2 in Burkina Faso.
View Article and Find Full Text PDFBiosens Bioelectron
November 2024
Department of Electrical Engineering, Pennsylvania State University, University Park, 16802, USA; Department of Biomedical Engineering, Pennsylvania State University, University Park, 16802, USA. Electronic address:
The human immunodeficiency virus (HIV) remains a major global health concern for which accurate viral load monitoring is essential for the management of HIV infection. The advent of antiretroviral therapy (ART) has transformed once-fatal HIV disease into a manageable chronic condition that now makes the need for VL testing which aims to satisfy international suppression targets 95-95-95 al l the more essential. Therefore, considering the complexity and diversity of HIV infection, it is essential to develop rapid diagnostic technologies suitable for different clinical situations.
View Article and Find Full Text PDFHeliyon
November 2024
HIV-1 Molecular Epidemiology Laboratory, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Microbiology Department, Hospital Universitario Ramón y Cajal, CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, 28034, Spain.
Background: There are 39 million people infected by the human immunodeficiency virus (HIV) and 1.3 million new annually infections with more than 150 variants circulating. Early HIV detection is crucial for timely antiretroviral therapy and transmission prevention, but no technique can detect HIV before 10 days of infection.
View Article and Find Full Text PDFRev Med Inst Mex Seguro Soc
February 2024
Instituto Politécnico Nacional, Escuela Nacional de Ciencias Biológicas. Ciudad de México, México.
Antiviral Res
December 2024
NHC Key Laboratory of Systems Biology of Pathogens, National Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China; Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. Electronic address:
Emerging studies demonstrate that lipid conjugation is a vital strategy for designing peptide-based viral fusion inhibitors, and the so-called lipopeptides exhibit greatly improved antiviral activity. In the design of lipopeptides, a flexible linker between the peptide sequence and lipid molecule is generally required, mostly with a short polyethylene glycol or glycine-serine sequence. Very recently, we discovered that the helix-facilitating amino acid sequence "EAAAK" as a rigid linker is a more efficient method in the design of SARS-CoV-2 fusion inhibitory lipopeptides.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!